Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study

Diabetes, Obesity and Metabolism

Volumn 20, Issue 7, 2018, Pages 1781-1786

  Fadini, Gian Paolo ^a   Zatti, Giancarlo ^a   Baldi, Ileana ^a   Bottigliengo, Daniele ^a   Consoli, Agostino ^b   Giaccari, Andrea ^c   Sesti, Giorgio ^d   Avogaro, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Universitario A Gemelli   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

cohort study; dapagliflozin; glycaemic control; observational study; type 2 diabetes; weight control

Indexed keywords

ALOGLIPTIN; DAPAGLIFLOZIN; EXENDIN 4; GLICLAZIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; AGED; AGONISTS; BLOOD PRESSURE; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLICLAZIDE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85044511723     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13280     Document Type: Article

References (17)

1. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515-531.
2. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262-275, e269.
3. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457-466.
4. Frieden TR. Evidence for health decision making - beyond randomized, controlled trials. N Engl J Med. 2017;377:465-475.
5. Patel A, Billot L. Reality and truth. Balancing the hope and the hype of real-world evidence. Circulation. 2017;136:260-262.
6. Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health. 2013;16:1054-1062.
7. Austin PC, Laupacis A. A tutorial on methods to estimating clinically and policy-meaningful measures of treatment effects in prospective observational studies: a review. Int J Biostat. 2011;7:6.
8. Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing propensity scores. Health Serv Res. 2014;49:1701-1720.
9. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
10. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
11. Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL population-based cohort study. Circulation. 2017. https://doi.org/10.1161/CIRCULATIONAHA.117.031227 [Epub ahead of print].
12. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose Cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose Cotransporter-2 inhibitors). Circulation. 2017;136:249-259.
13. Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A. Rationale and design of the DARWIN-T2D (DApagliflozin real world evIdeNce in type 2 diabetes): a multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017;27:1089-1097.
14. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671-679.
15. Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab. 2015;17:1075-1084.
16. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405-415.
17. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410-1418.